RE:Are trials going ok?Hi Ticktech.
Not sure if anyone has responded but I'll give it a try. There has been 15 years of continuous progress for this little biotech. I believe the trial you are referring to is ASSURE in which the top line data were released by Cleveland Clinic in June 2013 and rvx-208 failed to achieve the primary end point of PAV regression.
Since then the scientific progress in terms of understanding rvx-208 has been nothing short of remarkable in terms of understanding the MOA of rvx-208's epigenetic effects and they are multiple and powerful to say the least.
Now that RVX understand the MOA much better they have been able to move to a phase lll trial in the EU, China, South America and other countries called BETonMACE. The end point of this trial is MACE (major adverse cardiovascular events) reduction. The reason this was chosen is that in the post hoc analysis of the combined ASSURE/SUSTAIN trials RVX scientists discovered that within patients with diabetes mellitus and cardiovascular disease with low HDL that rvx-208 achieved a statistically significant relative risk reduction of MACE events of 77% and the absolute risk reduction was 16% points (=21% in control and 5% in the rvx-208 treated patients).
rvx-208 has demonstrated at highly statistically significant levels that it increases ApoA-l which is a key component. So rvx-208 increase functional HDL. Some CEPT inhibitors have increased HDL but it does not appear that the HDL produced this way is functional in reducing MACE.
So I suggest you review all of the scientific posts by BearDownAZ because he is a scientist and seems to have a very strong grasp of epigenetics, which is an emerging field in biotech. There are other science posters but I can remember them.
I also suggest you spend allot of time reading the various press releases by RVX. There has been remarkable progress in the past few years with this company - great science.
Good luck.
Toinv